Skip to main content

Rocklage Scott M's Form 4 filing

Entrada Therapeutics, Inc. (TRDA) · filed Nov 18, 2025

Accession no.
0001231919-25-000522
Filed
Nov 18, 2025, 4:34 PM ET
Trade date
Nov 14, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market sales total $1.76M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Rocklage Scott MCIK 000121901410% Owner
Schwab Andrew J.CIK 000159854910% Owner
5AM Ventures V, L.P.CIK 000167432410% Owner
5AM Opportunities I, L.P.CIK 000175300010% Owner
5AM Opportunities I (GP), LLCCIK 000179077810% Owner
5AM Partners V, LLCCIK 000179188910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 14, 2025Common StockSSaleDisposed−200,000$8.80F1−$1,760,0002,963,066DirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.023 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)